A hematologist and oncologist with Regional Cancer Care Associates (RCCA) in New Jersey, Kenneth D. Nahum, MD, has been practicing medicine for more than 30 years. In addition to treating patients, Dr. Kenneth D. Nahum has served as the principle and co-investigator on dozens of drug studies for the treatment of unresectable cancers.
Cancer that cannot be fully removed by surgery, unresectable cancer is not the same as untreatable cancer. Further, some tumors are initially deemed unresectable but later become removable.
Several factors contribute to a tumor being unresectable, including the tumor's size and location. When a tumor is large, removing it with surgery may require the removal of a large portion of an essential organ. This will negatively impact the function of the body and make safe removal of the growth difficult. The same is true if the tumor is intertwined with vital blood vessels.
Certain tumors may also be deemed unresectable because of their spread. Since surgery is a local treatment, it is not a viable option for tumors that have spread to other areas of the body. Chemotherapy, targeted therapy, and other systemic treatments that kill cancer cells in numerous areas of the body are preferred.
A hematologist and an oncologist with Regional Cancer Care Associates, LLC, Kenneth D. Nahum, DO, divides his time between treating patients and participating in clinical research. In addition to his involvement in clinical studies, Dr. Kenneth D. Nahum has co-written publications about different therapies for conditions like Waldenstrom’s macroglobulinemia (WM).
Seen in about six people per 1 million, WM is a type of lymphoma. People who have this condition produce too much immunoglobulin M (IgM), a type of protein. As a result, the blood becomes thicker than normal and moves through the blood vessels slower. WM cells can grow in the spleen, liver, bone marrow, or lymph nodes and are easily controlled due to their slow spreading.
The symptoms that appear with WM vary from person to person and may not appear for several years. Weakness is the most common symptom of WM since it results from having too few red blood cells in the body. This occurs when WM cells push out normal cells in the blood marrow. Weight loss, loss of appetite, and neuropathy, a pins-and-needles sensation in the legs, are also common for WM. Many of these symptoms are similar to certain types of non-Hodgkin lymphoma.
More aggressive cases of WM are often characterized by more extreme symptoms, known as B symptoms. These include severe skin itchiness, heavy sweating, and unexplained fever.
A distinguished hematologist and oncologist for the past 30 years, Kenneth D. Nahum is a recipient of the Humanitarian Physician of the year award from Kimball Medical Center. Currently serving at Regional Cancer Care Associates (RCCA) in New Jersey, Kenneth D. Nahum also supports medical advancements through contributions to his local chapter of the Juvenile Diabetes Research Foundation (JDRF).
One of the many ways JDRF supports patients with Type 1 diabetes (T1D) is through its artificial pancreas program. The artificial pancreas is a portable, convenient technology system that helps people managing T1D live a more normal life without the need to check blood-sugar levels or inject themselves with insulin multiple times per day.
Using a continuous glucose monitor (CGM) and insulin pump, the artificial pancreas responds to changes in the patient’s blood sugar level with an algorithm-based appropriate dosage at the right time. The technology is user-friendly, miniature, and not visible to anyone other than the user.
A hematologist and oncologist with Regional Cancer Care Associates (RCCA) in Howell, New Jersey, Kenneth D. Nahum has a distinguished clinical, research, and teaching career. In addition to his medical work, Kenneth D. Nahum and his wife support nonprofit and educational organizations, including the Solomon Schechter School of Monmouth County, more recently renamed the Hebrew Academy of New Jersey.
To spur 21st-century learning and train students for the digital age, the Hebrew Academy features a state-of-the-art technology lab on campus. Once a basic school library and computer room, the school upgraded its technology center in 2013, equipping the space with 20 iMac computers and 30 iPad tablets.
During their time in the technology lab, students learn how to perform Internet research, access learning tools available on the computers, and navigate other digitized resources. They also use learning applications and connect via video chats with other students and teachers across the globe.
An oncologist and hematologist at Regional Cancer Care Associates (RCCA), Dr. Kenneth D. Nahum has been working as a physician for more than three decades. In that time, Dr. Kenneth D. Nahum has joined several professional organizations, including the American College of Physicians (ACP).
The world’s largest society for internal medicine specialists and subspecialists, ACP advances the practice of internal medicine by providing professionals with a variety of education and networking opportunities. This includes the organization’s Internal Medicine Meeting, an annual conference that provides attendees with access to hands-on sessions and presentations that keep them updated on advances in their field.
Designed for hospitalists, general internists, family physicians, residents, and subspecialists in internal medicine, the ACP Internal Medicine Meeting 2019 is scheduled for April 11-13 at the Pennsylvania Convention Center in Philadelphia. ACP will host more than 200 scientific sessions and offer attendees a maximum of 30.5 category 1 AMA credits. These credits can be used toward a professional’s maintenance of certification (MOC) or continuing medical education (CME) efforts.
Hematologist and oncologist Dr. Kenneth D. Nahum practices with Regional Cancer Care Associates (RCCA) in New Jersey. Possessing more than 30 years of experience in medicine, Dr. Kenneth D. Nahum has treated thousands of patients and studied new treatment options for metastatic cancers.
Metastasis refers to cancer that has spread from one organ to other parts of the body. This occurs when cancer cells break from the original tumor and move through the lymph system or bloodstream to new locations.
Most of the time, cancers of varying types metastasize to the lungs, brain, bones, and liver. However, cancer cells can grow in other areas, including the skin, adrenal gland, and muscle. The location of metastatic cancer largely affects the symptoms a patient experiences.
In certain cases, metastasis is not accompanied by any symptoms. Because of this, the condition can be difficult to diagnose if patients do not have a follow-up care plan.
For more than three decades, Dr. Kenneth D. Nahum has treated patients with blood disorders and cancer as a hematologist-oncologist. Practicing at Regional Cancer Care Associates, Dr. Kenneth D. Nahum has cared for thousands of patients over the years, in addition to undertaking clinical research on such conditions as multiple myeloma.
A type of blood cancer, multiple myeloma causes the body to release too much protein, which builds up and eventually damages the organs. Although scientists have not identified a specific cause, they have linked the condition to the presence of an abnormal plasma cell in the bone marrow. This abnormal cell rapidly multiplies and overwhelms healthy cell production, pushing healthy cells out of the bone marrow and leaving a high number of multiple myeloma cells.
This abnormal cell may be the result of either a mutation in the oncogenes, a part of the DNA that contains instructions for how to grow and divide cells, or an abnormality in the chromosomes. Several studies have revealed that people with multiple myeloma are missing parts of the 17th chromosome in their DNA, while others have found that people with the condition have one chromosome switched with another.
Award-winning physician Kenneth D. Nahum works as a hematologist and oncologist at Regional Cancer Care Associates in New Jersey. Possessing more than three decades of experience, Dr. Kenneth D. Nahum has treated a wide range of cancers, including non-small cell lung cancer (NSCLC).
Roughly 80 percent to 85 percent of all lung cancers are classified as NSCLC. This classification is based on the microscopic appearance of the tumor cells.
The bulk of NSCLC cancers in the United States are adenocarcinomas. While these cancers are associated with smoking, they can also appear in people who do not smoke. Most often, adenocarcinomas develop in the outer areas of the lungs and spread to the lymph nodes and then throughout the body.
After adenocarcinomas, the most common form of NSCLC is squamous cell carcinoma. Roughly 25 percent to 30 percent of all lung cancer cases involve squamous cell carcinomas.
In most cases, these types of cancer grow in the central chest area in the bronchi. From there, they can spread to the lymph nodes, but they normally stay in the lungs.
Finally, about 10 percent to 15 percent of all lung cancers are categorized as large-cell or undifferentiated carcinomas. An aggressive form of lung cancer, large-cell carcinomas rapidly spread to the lymph nodes and other areas of the body.
This aggressive nature is also seen in small-cell lung cancers (SCLC), the classification that includes all lung cancers not in the NSCLC category.
Specializing in treating patients with blood cancers and other blood disorders, Kenneth D. Nahum, DO, has served as a hematologist and oncologist with Regional Cancer Care Associates, LLC, since 2012. Continually honing his education in the field, Dr. Kenneth D. Nahum belongs to the American Society of Clinical Oncology (ASCO).
A recent study featured in JAMA: The Journal of the American Medical Association shows that economic background can play a significant role in the quality of cancer care that patients receive. ASCO President Monica M. Bertagnolli, MD, FACS, FASCO, commented on the study’s findings by affirming the conclusion that advances in cancer care have not always translated into better outcomes, especially for those who come from low-income backgrounds.
ASCO also joined JAMA researchers in urging policymakers and other stakeholders to push for public health initiatives targeting underserved areas to help them get access to better cancer care. The organization has been partnering with local health departments to provide smoking cessation courses and says it will continue to work with other public health entities to address other issues, such as smoking, obesity, and lack of physical activity, that tend to be more prevalent in patients from lower-income backgrounds.
Award-winning physician Kenneth D. Nahum practices with Regional Cancer Care Associates (RCCA) as a hematologist and oncologist. Possessing more than three decades of experience, Dr. Kenneth D. Nahum has helped thousands of patients with various disorders, including hemophilia.
An inherited disorder on the X chromosome, hemophilia prevents the proper clotting of blood. Since women inherit two X chromosomes, one from each parent, they are less likely to develop hemophilia than men.
The presence of a second X chromosome prevents the development of this condition in many women, providing a second copy of the same genes. Men do not have this second copy since they have one X chromosome and one Y chromosome, which allows the mutated X chromosome to have more of an impact.
In most cases, women are carriers of hemophilia. However, about a third of these women also display mild hemophilia symptoms, such as impaired blood clotting. These women may have approximately 30 to 70 percent of the blood-clotting ability of someone who is not a carrier of the hemophilia mutation.
Carriers may experience heavy menstrual periods characterized by clots larger than a quarter, bleeding for more than seven days, or a large amount of blood that limits daily activities. Heavy bleeding from childbirth or dental surgery is also common among women who carry the hemophilia mutation.
Some women are diagnosed with hemophilia because they either inherited a mutated X chromosome from both parents, meaning they have two mutated X chromosomes, or their non-mutated X chromosome is either inactive or missing. This situation is extremely rare, but it does result in hemophilia symptoms similar to the symptoms in males with hemophilia.
A practicing partner of Regional Cancer Care Associates, Dr. Kenneth D. Nahum, DO, has over 30 years of experience treating cancer patients in New Jersey and surrounding areas.